Latest News
Aspen, South Africa’s leading pharmaceutical company, has announced that all conditions precedent have been met for it to acquire the pharmaceutical business of Australian-based Sigma Pharmaceuticals Limited.
Read More >>On 16 August 2010, Sigma announced that it had agreed in principle to sell its Pharmaceuticals Division to the Aspen Pharmacare Holdings Limited group of companies for A$900 million.
Read More >>Effective immediately, Aspen is taking over the sales, distribution and marketing of a portfolio of dermatology products from Merck, with estimated annual sales of $50 million.
Read More >>An interview of Stephen Saad, CEO of Aspen Holdings.
Read More >>Announcement regarding the acquisition of the pharmaceutical business of Sigma Pharmaceuticals Limited by Aspen.
Read More >>Aspen shareholders are advised that Aspen has submitted an indicative non-binding proposal to acquire, either directly or through a wholly-owned subsidiary, Sigma Pharmaceuticals Limited.
Read More >>Aspen, Africa’s largest pharmaceutical manufacturer, has announced that it has agreed to multiple, strategic, inter-dependent transactions with a leading multinational pharmaceutical group, GlaxoSmithKline.
Read More >>Aspen’s high level of flexibility has shown demonstrable business outcomes in addition to the attraction/retention of diverse talent, including consistently meeting sales objectives and extremely high value customer relationships.
Read More >>Aspen Pharmacare have signed a licensing agreement with Sanofi-Aventis for the distribution, sales and marketing of Tritace and Cardizem.
Read More >>Aspen Australia have signed a license agreement with Actavis, taking on the sales, marketing and distribution of two products, Neotigason and Rapilysin.
Read More >>- « Previous
- 1
- 2
- 3
- 4